Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 346

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Antitumor Effects of Chimeric Receptor Engineered Human T Cells Directed to Tumor Stroma

Open access
Kakarla, Sunitha, Chow, Kevin KH, Mata, Melinda, Shaffer, Donald R, Song, Xiao-Tong, Wu, Meng-Fen, Liu, Hao, Wang, Lisa L, Rowley, David R, Pfizenmaier, Klaus, Gottschalk, Stephen·2013·Molecular Therapy

Abstract

Cancer-associated fibroblasts (CAFs), the principle component of the tumor-associated stroma, form a highly protumorigenic and immunosuppressive microenvironment that mediates therapeutic resistance. Co-targeting CAFs in addition to cancer cells may therefore augment the antitumor response. Fibroblast activation protein-α (FAP), a type 2 dipeptidyl peptidase, is expressed on CAFs in a majority of solid tumors making it an attractive immunotherapeutic target. To target FAP-positive CAFs in the tumor-associated stroma, we genetically modified T cells to express a FAP-specific chimeric antigen receptor (CAR). The resulting FAP-specific T cells recognized and killed FAP-positive target cells as determined by proinflammatory cytokine release and target cell lysis. In an established A549 lung cancer model, adoptive transfer of FAP-specific T cells significantly reduced FAP-positive stromal cells, with a concomitant decrease in tumor growth. Combining these FAP-specific T cells with T cells that targeted the EphA2 antigen on the A549 cancer cells themselves significantly enhanced overall antitumor activity and conferred a survival advantage compared to either alone. Our study underscores the value of co-targeting both CAFs and cancer cells to increase the benefits of T-cell immunotherapy for solid tumors.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/mt.2013.110

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 346

Metadata

Authors
Kakarla, S., Chow, K. K., Mata, M., Shaffer, D. R., Song, X.-T., Wu, M.-F., Liu, H., Wang, L. L., Rowley, D. R., Pfizenmaier, K., & Gottschalk, S.
Venue
Molecular Therapy
Publisher
Elsevier BV
Published
2013-08
Volume
21
Issue
8
Pages
1611-1620
ISSN
1525-0016 (ISSN-L)
OpenAlex
W2036144830
Cited by
346
References
10
FWCI
7.43
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Antitumor Effects of Chimeric Receptor Engineered Human T Cells Directed to Tumor Stroma. https://app.cochat.ai/papers/10.1038/mt.2013.110
The paper
Kakarla, S., Chow, K. K., Mata, M., Shaffer, D. R., Song, X.-T., Wu, M.-F., Liu, H., Wang, L. L., Rowley, D. R., Pfizenmaier, K., & Gottschalk, S. (2013). Antitumor Effects of Chimeric Receptor Engineered Human T Cells Directed to Tumor Stroma. Molecular Therapy. https://doi.org/10.1038/mt.2013.110

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.